Advances in Immunotherapy for T Cells and Tumors
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Cellular/Molecular Immunology".
Deadline for manuscript submissions: closed (15 March 2025) | Viewed by 1648
Special Issue Editor
Special Issue Information
Dear Colleagues,
Cancer is a devastating disease which has been and continues to be one of the main threats to human health. Traditional cancer treatments, including surgery, chemotherapy, and radiation therapy, have demonstrated very limited efficacy for patients with late-stage disease. In addition, chemotherapy and radiotherapy often cause considerable side effects. Therefore, innovative and effective cancer treatments are urgently needed for cancer patients with late-stage and refractory disease. Immunotherapy has become an established pillar of cancer treatment improving the prognosis of many patients with a broad variety of hematological and solid malignancies.
This Special Issue welcomes reviews, as well as original articles related to research on a broad range of immunotherapy treatments, including cellular therapies, vaccines, and ICB; the identification of new predictive biomarkers and therapeutic targets; novel therapeutic approaches; and the use of immune modulators to overcome immune resistance, among others.
Dr. Zhichen Sun
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer immunotherapy
- immunotherapy
- tumors
- T cell
- vaccines
- immune resistance
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
